---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-015517"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2024-01-25T23:59:59+00:00"
generated_at: "2026-06-06T17:46:21.366489+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Jazz reprices $2.72B term loans; margin cut 50 bps to Term SOFR+3.00%

## Summary
- Existing $2.7225B Initial Dollar Term Loans refinanced into same principal of Tranche B-1 Dollar Term Loans.
- New margin set at Term SOFR+3.00% (prime+2.00%), down from SOFR+3.50%; Term SOFR floor 0.50%.
- Additional $201.9M borrowed to repay Initial Dollar Term Loans that were not converted.
- Maturity unchanged at May 5, 2028; quarterly amortization at 0.2847% of initial principal.
- Repricing effective January 19, 2024; no change to covenants or security package.

## SEC filing metadata
- accession: 0001193125-24-015517
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2024-01-25T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312524015517/0001193125-24-015517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312524015517/d707707d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-015517
- JSON: https://secwatch.observer/filing/0001193125-24-015517.json
- Plain text: https://secwatch.observer/filing/0001193125-24-015517.txt

## Key facts
- Debt Financings
  Jazz Pharmaceuticals plc incurred term loan of $201,909,488.38 aggregate principal amount of additional Tranche B-1 Dollar Term Loans maturing May 5, 2028.
  - Instrument: term loan
  - Principal: $201,909,488.38 aggregate principal amount of additional Tranche B-1 Dollar Term Loans
  - Maturity: May 5, 2028
  - Event: incurrence
  source text: Jazz Lux borrowed $201,909,488.38 aggregate principal amount of additional Tranche B-1 Dollar Term Loans
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000119312524015517/0001193125-24-015517-index.htm
- Debt Financings
  Jazz Pharmaceuticals plc amended credit facility with Bank of America, N.A. at Term SOFR plus 3.00% (with a floor of 0.50%) or the prime lending rate plus 2.00.
  - Instrument: credit facility
  - Counterparty: Bank of America, N.A.
  - Rate: Term SOFR plus 3.00% (with a floor of 0.50%) or the prime lending rate plus 2.00
  - Event: amendment
  source text: The applicable margin for the Tranche B-1 Dollar Term Loans is 3.00% (in the case of Term SOFR borrowings) and 2.00% (in the case of borrowings at the prime lending rate), a decrease of 50 basis points from the applicable margin on the Initial Dollar Term Loans
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000119312524015517/0001193125-24-015517-index.htm
- Material Agreements
  Jazz Pharmaceuticals plc amended Repricing Amendment with Bank of America, N.A., as administrative agent and U.S. Bank Trust Company, National Association, as collateral trustee (effective 2024-01-19).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Bank of America, N.A., as administrative agent and U.S. Bank Trust Company, National Association, as collateral trustee
  - Effective: 2024-01-19
  source text: abilité limitée ) incorporated and existing under the laws of Luxembourg (“Jazz Lux”) and wholly owned subsidiary of Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in Ireland (the “Company”), entered into an amendment (the “Repricing Amendment”) to the Credit Agreement, dated May 5, 2021, by and among Jazz Lux and certain other subsidiaries of the Company, as borrowers (collectively with the Company and Jazz Lux, the “Borrowers”), the lenders and issuing banks from time to time party thereto, Bank of America, N.A., as administrative agent and U.S.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000119312524015517/0001193125-24-015517-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.